glp 1 agonist example Frontiers America's Poison Centers - GLP-1

Drucker, Glucagon-like Peptide-1 Receptor-based Therapeutics for Metabolic Liver Disease, Endocrine Reviews, 2023, 44, 1432

Now the next wave is shaping up to go even further beyond simple GLP-1 monotherapy

Glucagon is traditionally viewed as the opposite of insulin, a hormone that raises blood sugar by stimulating the liver to release stored glucose

Based on todays evidence: Injections produce the highest overall weight loss Oral options offer unmatched convenience with strong early results Both are effective for people with obesity or type 2 diabetes For many patients, the choice is not just which is stronger? But its which is easier to stay on long-term? Side Effects: What the Study Found The clinical trial results for GLP-1 treatments show that orforglipron has a similar side-effect pattern to other GLP-1 receptor agonists: most issues are gastrointestinal and mild to moderate